Program Overview
Many CKD patients also experience complex and compounding burdens of disease, particularly once they progress to the stage of requiring hemodialysis. This notably includes anemia (aCKD), which is associated with a reduced quality of life and increased morbidity and mortality. Encouraging clinical trial data have recently emerged for hypoxia-inducible, factor prolyl hydroxylase inhibitor (HIF-PHI) therapeutics for patients on dialysis for CKD. This novel, targeted therapy is now FDA-approved and appears promising; healthcare providers should receive a data update on it. In addition, we recognize that the progressive and incurable nature of CKD remains a challenging journey for patients, specifically those undergoing dialysis. Optimal care and support of these patients and their caregivers are characterized by guidelines-concordant management of the kidney disease and related comorbidities, as well as a thorough understanding of stubborn disparities in the healthcare system that result in unequal access to high-quality care and improved outcomes.
Target Audience
Nephrologists, other internists, primary care providers, NPs and PAs, pharmacists, and other healthcare providers who care for patients with chronic kidney disease that is dialysis-dependent
Learning Objectives
- Understand the pathophysiology of chronic kidney disease anemia, unmet patient needs, and the overall burden of disease for patients on hemodialysis
- Analyze clinical trial data and clinical applications for hypoxia-inducible, factor prolyl hydroxylase inhibitor (HIF-PHI) therapeutics for patients on hemodialysis for CKD
- Collaborate with the healthcare team to address care disparities in the management of patients with CKD-associated anemia undergoing dialysis
Agenda
I. Introduction, Welcome, Objectives – Jay Wish, MD
II. Stage 5 CKD Pathophysiology, Burden of Disease, and Unmet Patient Needs, and the Progression to Dialysis Dependency – Sophia Ambruso, MD
III. Science, Clinical Trial Update, and Potential Clinical Applications for Hypoxia-Inducible Factor Prolyl Hydroxylase Inhibitor (HIF-PHI) Therapeutics for Patients on Hemodialysis for CKD – Robert Provenzano, MD
IV. Strategies to Address Care Delivery Disparities in the Management of Patients with CKD-Associated Anemia Undergoing Dialysis – Christine Chmielewski, NP and Jay Wish, MD
V. Faculty Panel Discussion – Jay Wish, MD and Faculty
Faculty
Jay B. Wish, MD (Course Chair)
Medical Director, Out-Patient Dialysis Unit
Indiana University Hospital
Chief Medical Officer for Dialysis, IU Health
Professor of Clinical Medicine
Indiana University School of Medicine
Indianapolis, Indiana
Sophia Ambruso, MD
Clinical Nephrologist
Rocky Mountain VA Medical Center
Assistant Professor
University of Colorado
Aurora, Colorado
Christine M. Chmielewski, CRNP
Nephrology Nurse Practitioner
Thomas Jefferson University Hospital
Philadelphia, Pennsylvania
Robert Provenzano, MD
Associate Clinical Professor of Medicine
Wayne State University School of Medicine
Detroit, Michigan
Disclosures of Relevant Financial Relationships
It is the policy of AcademicCME that all faculty, instructors, and planners disclose relevant financial relationships relating to the topics of this educational activity. Any relevant financial relationships are mitigated via a content review by planning committee members and faculty with no relevant financial relationships.
The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CE activity:
| Faculty | Relationship Identified With: |
| Jay B. Wish, MD (Course Chair)
|
Consultant/Advisor: Akebia; AstraZeneca; Dexcel Pharma; Disc Medicine; GlaxoSmithKline; Otsuka Pharmaceuticals
Speaker’s Bureau: AstraZeneca; Akebia; GlaxoSmithKline |
| Christine M. Chmielewski, MS, CRNP
|
Consultant/Advisor: GlaxoSmithKline; Vifor
Speaker’s Bureau: AstraZeneca |
| Robert Provenzano, MD
|
Consultant/Advisor: GlaxoSmithKline; FibroGen, Inc.
Stocks: Organic Arthritis; Nephroceuticals; Vasc-Alert |
| Sophia Ambruso, MD
|
Consultant/Advisor: AstraZeneca; GlaxoSmithKline |
Planners and Peer Reviewers
Timothy Hayes, MD, PhD; Kim Cheramie, MSN, RN-BC; Nicole McMenamin and Chelsey Simonds hereby state that they or their spouse/life partner do not have any relevant financial relationships to products or devices with any commercial interests related to the content of this activity of any amount during the past 12 months.
Accreditation Statement
In support of improving patient care, AcademicCME is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Credit Designation Statements
AcademicCME designates this enduring material for a maximum of 1.0 AMA PRA Category 1 CreditTM.
AcademicCME designates this enduring material for a maximum of 1.0 CNE Contact Hour, including 1.0 Pharmacotherapeutic Contact Hour (Provider #P0491).
Participants should claim only the credit commensurate with the extent of their participation in the activity.
Financial Support
This activity has been supported by an independent educational grant from GlaxoSmithKline.
Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. AcademicCME and GlaxoSmithKline do not recommend the use of any agent outside of the labeled indications.
Disclaimer
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
Method of Participation
In order to claim credit, participants must complete the following:
- Read the learning objectives, accreditation information and faculty disclosures at the beginning of this activity.
- Complete the Pre-Activity Questions
- Read or Review the activity content.
- Complete the Post-Activity Test Questions and Evaluation.
- Learners who receive a grade of 75% or better on the Post-Activity Test Questions and complete the Evaluation will receive appropriate credit as indicated (CME, CNE, and/or CPE credit).
- CME and CNE credit will be issued appropriate certificate of completion.
- Others may request a “certificate of completion”.
- Learners should claim only the credit commensurate with the extent of their participation in the activity.
CE Inquiries/Special Needs
For all CE inquiries or special needs, please contact [email protected].
